Abstract:In contrast to normal cells, cancer cells avidly take up glucose and metabolize it to lactate even when oxygen is abundant, a phenomenon referred to as the Warburg effect. This fundamental alteration in glucose metabolism in cancer cells enables their specific detection by positron emission tomography (PET) following i.v. injection of the glucose analogue (18)F-fluorodeoxy-glucose ((18)FDG). However, this useful imaging technique is limited by the fact that not all cancers avidly take up FDG. To identify molecular determinants of (18)FDG retention, we interrogated the transcriptomes of human-cancer cell lines and primary tumors for metabolic pathways associated with (18)FDG radiotracer uptake. From ninety-five metabolic pathways that were interrogated, the glycolysis, and several glycolysis-related pathways (pentose phosphate, carbon fixation, aminoacyl-tRNA biosynthesis, one-carbon-pool by folate) showed the greatest transcriptional enrichment. This "FDG signature" predicted FDG uptake in breast cancer cell lines and overlapped with established gene expression signatures for the "basal-like" breast cancer subtype and MYC-induced tumorigenesis in mice. Human breast cancers with nuclear MYC staining and high RNA expression of MYC target genes showed high (18)FDG-PET uptake (P < 0.005). Presence of the FDG signature was similarly associated with MYC gene copy gain, increased MYC transcript levels, and elevated expression of metabolic MYC target genes in a human breast cancer genomic dataset. Together, our findings link clinical observations of glucose uptake with a pathologic and molecular subtype of human breast cancer. Furthermore, they suggest related approaches to derive molecular determinants of radiotracer retention for other PET-imaging probes.

Supplementary Figure 4 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 3 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 2 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures 1-4 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure Legends 1-4, Methods from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Tables 1-5 from <sup>18</sup>F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers

Supplementary Figure 2 from Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

Supplementary Figure 1 from Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15Q24-25.1

Supplementary Figure 3 from HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer Cells

Supplementary Figure from Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Supplementary Figure 5 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 2 from &Lt;i>fra-1&Lt;/i> Promotes Breast Cancer Chemosensitivity by Driving Cancer Stem Cells from Dormancy

Figure S1 from Use of <i>ex</i> <i>vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>her2</i> Mutant Non–Small Cell Lung Cancer

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Figure 4 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 4 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 1 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 3 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure 2 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figures 1-4 from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers

Supplementary Figure Legends 1-4, Methods from &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers